The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
Open accessAbstract
Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. Methods: We used individual patient data from the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database, which includes all patients randomized in the 4 pivotal trials of DOACs versus warfarin in atrial fibrillation (RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), to perform network meta-analyses using a stratified Cox model with random effects comparing standard-dose DOAC, lower-dose DOAC, and warfarin. Hazard ratios (HRs [95% CIs]) were calculated for efficacy and safety outcomes. Covariate-by-treatment interaction was estimated for categorical covariates and for age as a continuous covariate, stratified by sex. Results: A total of 71 683 patients were included (29 362 on standard-dose DOAC, 13 049 on lower-dose DOAC, and 29 272 on warfarin). Compared with warfarin, standard-dose DOACs were associated with a significantly lower hazard of stroke or systemic embolism (883/29 312 [3.01%] versus 1080/29 229 [3.69%]; HR, 0.81 [95% CI, 0.74–0.89]), death (2276/29 312 [7.76%] versus 2460/29 229 [8.42%]; HR, 0.92 [95% CI, 0.87–0.97]), and intracranial bleeding (184/29 270 [0.63%] versus 409/29 187 [1.40%]; HR, 0.45 [95% CI, 0.37–0.56]), but no statistically different hazard of major bleeding (1479/29 270 [5.05%] versus 1733/29 187 [5.94%]; HR, 0.86 [95% CI, 0.74–1.01]), whereas lower-dose DOACs were associated with no statistically different hazard of stroke or systemic embolism (531/13 049 [3.96%] versus 1080/29 229 [3.69%]; HR, 1.06 [95% CI, 0.95–1.19]) but a lower hazard of intracranial bleeding (55/12 985 [0.42%] versus 409/29 187 [1.40%]; HR, 0.28 [95% CI, 0.21–0.37]), death (1082/13 049 [8.29%] versus 2460/29 229 [8.42%]; HR, 0.90 [95% CI, 0.83–0.97]), and major bleeding (564/12 985 [4.34%] versus 1733/29 187 [5.94%]; HR, 0.63 [95% CI, 0.45–0.88]). Treatment effects for standard- and lower-dose DOACs versus warfarin were consistent across age and sex for stroke or systemic embolism and death, whereas standard-dose DOACs were favored in patients with no history of vitamin K antagonist use ( P =0.01) and lower creatinine clearance ( P =0.09). For major bleeding, standard-dose DOACs were favored in patients with lower body weight ( P =0.02). In the continuous covariate analysis, younger patients derived greater benefits from standard-dose (interaction P =0.02) and lower-dose DOACs (interaction P =0.01) versus warfarin. Conclusions: Compared with warfarin, DOACs have more favorable efficacy and safety profiles among patients with atrial fibrillation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744
Self-citationEikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Subgroup analyses in randomized trials: risks of subgroup-specific analyses;
Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.08.009 · Cited by 775
Chi-squared goodness-of-fit tests for the proportional hazards regression model
SCHOENFELD, D. (1980) · Biometrika · doi:10.1093/biomet/67.1.145 · Cited by 489
An introduction to multiplicity issues in clinical trials: the what, why, when and how
Li, G., Taljaard, M., Van den Heuvel, E. R., Levine, M. A., Cook, D. J., Wells, G. A., Devereaux, P. J., & Thabane, L. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw320 · Cited by 381
The strengths and limitations of meta-analyses based on aggregate data
Lyman, G. H., & Kuderer, N. M. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-14 · Cited by 250
Desai, J., Kolb, J., Weitz, J., & Aisenberg, J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0150 · Cited by 191
Ioannidis, J. (2017) · British Journal of Sports Medicine · doi:10.1136/bjsports-2017-097621 · Cited by 188
Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes
Smith, C. T., Williamson, P. R., & Marson, A. G. (2005) · Statistics in Medicine · doi:10.1002/sim.2050 · Cited by 173
Ezekowitz, M. D., Wallentin, L., Connolly, S. J., Parekh, A., Chernick, M. R., Pogue, J., Aikens, T. H., Yang, S., Reilly, P. A., Lip, G. Y. H., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.973735 · Cited by 170
Self-citationEffects of dabigatran according to age in atrial fibrillation
Lauw, M. N., Eikelboom, J. W., Coppens, M., Wallentin, L. C., Yusuf, S., Ezekowitz, M. D., Oldgren, J., Nakamya, J., Wang, J., & Connolly, S. J. (2017) · Heart · doi:10.1136/heartjnl-2016-310358 · Cited by 96
Self-citationMunoz, F. D., Gharacholou, S. M., Munger, T. M., Friedman, P. A., Asirvatham, S. J., Packer, D. L., & Noseworthy, P. A. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.046 · Cited by 83
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
Vanassche, T., Hirsh, J., Ginsberg, J. S., & Eikelboom, J. W. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0346 · Cited by 66
Self-citationAnticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Schäfer, A., Flierl, U., Berliner, D., & Bauersachs, J. K. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06981-3 · Cited by 60
Garcia, D. A., Wallentin, L. C., Lópes, R. D., Thomas, L. E., Alexander, J. H., Hylek, E. M., Ansell, J., Hanna, M., Lanas, F. T., Flaker, G. C., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.016 · Cited by 53
Self-citationMitchell, A., Watson, M. C., Welsh, T. J., & McGrogan, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040554 · Cited by 52
Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy
Mahaffey, K. W., WOJDYLA, D. M., Hankey, G. J., White, H. D., Nessel, C. C., Piccini, J. P., Patel, M. R., Berkowitz, S. D., Becker, R. C., Halperin, J. L., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-12-201306180-00003 · Cited by 51
Self-citationO’Donoghue, M. L., Ruff, C. T., Giugliano, R. P., Murphy, S. A., Grip, L. T., Mercuri, M. F., Rutman, H., Shi, M., Kania, G., Čermák, O., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv014 · Cited by 47
Self-citationBoriani, G., Ruff, C. T., Kuder, J., Shi, M., Lanz, H., Antman, E. M., D, E. B. M., & Giugliano, R. P. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1716540 · Cited by 44
Self-citationCarnicelli, A., Hong, H., Giugliano, R. P., Connolly, S. J., Eikelboom, J. W., Patel, M. R., Wallentin, L. C., Morrow, D. A., WOJDYLA, D. M., Hua, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.12.002 · Cited by 38
Self-citationHong, H., Fu, H., Price, K. L., & Carlin, B. P. (2015) · Statistics in Medicine · doi:10.1002/sim.6519 · Cited by 35
Self-citationConduct and reporting of individual participant data network meta-analyses need improvement
Chaimani, A. (2020) · BMC Medicine · doi:10.1186/s12916-020-01630-w · Cited by 6
Cited by
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Self-citationJoglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Self-citation2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933
Self-citationPostoperative atrial fibrillation: from mechanisms to treatment
Gaudino, M., Di Franco, A., Rong, L. Q., Piccini, J., & Mack, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad019 · Cited by 259
Self-citation
Metadata
- Authors
- Carnicelli, A. P., Hong, H., Connolly, S. J., Eikelboom, J., Giugliano, R. P., Morrow, D. A., Patel, M. R., Wallentin, L., Alexander, J. H., Cecilia Bahit, M., Benz, A. P., Bohula, E. A., Chao, T.-F., Dyal, L., Ezekowitz, M., A.A. Fox, K., Gencer, B., Halperin, J. L., Hijazi, Z., Hohnloser, S. H., Hua, K., Hylek, E., Toda Kato, E., Kuder, J., Lopes, R. D., Mahaffey, K. W., Oldgren, J., Piccini, J. P., Ruff, C. T., Steffel, J., Wojdyla, D., Granger, C. B., & on behalf of the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators
- Venue
- Circulation
- Published
- 2022-01-25
- Volume
- 145
- Issue
- 4
- Pages
- 242-255
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4205709732
- Cited by
- 386
- References
- 30
- FWCI
- 49.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.